A Screen of FDA-Approved Drugs Identifies Inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or PRL-3) by Rivas, Dylan R. et al.
1 
Supplemental Material 
A Screen of FDA-approved drugs identifies inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or 
PRL-3) 
Dylan R. Rivas1#, Mark Vincent C. Dela Cerna2#, Caroline N. Smith1, Shilpa Sampathi1, Blaine G. 
Patty1, Donghan Lee2,3*, Jessica S. Blackburn1,4* 
1. University of Kentucky, Department of Molecular and Cellular Biochemistry, Lexington KY 40536,
USA
2. University of Louisville, Department of Biochemistry and Molecular Genetics, Louisville, KY 20202,
USA
3. James Graham Brown Cancer Center, Department of Medicine, Louisville KY 40202, USA
4. Markey Cancer Center, Lexington KY 40536, USA
*donghan.lee@louisville.edu
*jsblackburn@uky.edu









Supplemental Figure 1. Establishing the efficacy of the DiFMUP assay in assessing PRL 
phosphatase activity. A) SDS-PAGE gel demonstrating purity of PRL proteins used in the DiFMUP 
assay. B) PRL dephosphorylation of DiFMUP measured at ex=360nm and em=460nm. RFU=relative 
fluorescence units. C) Inhibition of PRL phosphatase activity by known inhibitors, ***p<.0001 compared 
to the negative control dexamethasone, an FDA-approved drug that is not expected to inhibit PRL 
activity. Bars represent the average of n=3, and are representative of 3 experiments. Standard 
deviation is shown.   
  





Supplemental Figure 2. A subset of hits from the initial screen failed re-analysis. The effects of 
broad PRL inhibitors on PRL phosphatase activity were examined. While these drugs hit in the initial 
screen, they did not meet the cut-off of >80% inhibition. Drugs were used at 40µM, bars are average 






Supplemental Figure 3. Dose response curves of FDA-approved drugs against PRL-1 and PRL-
2. Dose response curves showing DiFMUP phosphatase activity of PRL-1 (a,b) and PRL-2 (c,d) when 
treated with doses ranging between 1 nM and 100 µM of drug. Inhibition of PRL phosphatase activity 
by the broad PRL family inhibitors are shown, and drugs are subdivided into those with (a,c) high IC50 

























Supplemental Figure 4. Dose response curves of PRL-3 specific drugs. (a-f) Inhibition of 
phosphatase activity by PRL-3 specific compounds. Each data point is the average DiFMUP 
phosphatase activity of each PRL when treated with the drug dose noted. Assay were run in technical 





Supplemental Figure 5. PRL-3 expression in various cell lines. PRL-3 expression was 
assessed by western blots of cell lysates of (a) HEK293T cells transfected with the 
overexpression plasmids indicated, (b) HEK293T, HCT-116 and SW480 colorectal cancer cells 
for endogenous PRL-3, and (c) HCT-116 transfected with the shRNA plasmids indicated. 
Recombinant PRl-3 was used as a size control, and the total protein loaded into the gel is 








Supplemental Figure 6. Negative hits in the cell migration assay. Migration of vector control and 
PRL-3 overexpressing HEK293T cells after treatment with (a) Idasanutlin, (b) Napabucasin, and (c) 
YM155 at the concentrations indicated. Migration was measured as the area units migrated 24 hours 
after scratch. Percent migration was measured as the area units migrated 24 hours after scratch 
normalized to the area units migrated by 1% DMSO control treated cells withing the same dataset. All 
assays were run in duplicate wells, in 3 independent experiments. Statistics were done using one way 
ANOVA with Tukey HSD; there is no significant difference between any of the treatment groups. 
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Supplemental Figure 7. Salirasib and Candesartan did not significantly impact cell cycle or 
apoptosis in HEK293T, HCT-116 or SW480 cells. Flow cytometry analysis of EdU staining to assess 
cell cycle in HEK293T (a), HCT-116 (b), and SW480 (c) cells treated with either 1% DMSO, 100 µM 
Salirasib or 25 µM Candesartan for 24hr.  (d-e) shows cell cycle effects after 48hr drug treatment, in 
the same cell lines. Apoptosis of cells treated with either 1% DMSO, 100 µM Salirasib or 25 µM 
Candesartan for 24hr was quantified by AnnexinV plus propidium iodide staining. Flow cytometry was 
used to quantify staining in HEK293T (g), HCT-116 (h), and SW480 (i) cells. (j-l) shows AnnexinV + 
propidium iodide staining on the same cell lines treated with drug for 48hr. There is no significant 




Supplemental Figure 8. Phospho-ERK1/2 is reduced in drug treated cells. HCT116 colorectal 
cancer cells were treated for  24 hr with either 1% DMSO, 100 µM Salirasib, 25 µM Candesartan, or 25 
µM Thienopyridone, a known PRL inhibitor. PRL-3 has been previously found to regulate ERK signaling 
in colorectal cancer cells. Expected size of ERK1/2 is 44kD and 42kD, respectively. Total protein is 






Supplemental Figure 9. Representative images from scratch assays presented in Figure 5. 
HCT-116  cells were transfected with expression plasmids containing either scrambled/non-
targeting shRNA, or shRNAs targeting PRL-3 (#5 and #7). Cells were selected with puromycin for 
48 hours then plated as a monolayer of cells. The monolayer was scratched with a pipet tip and 
immediately imaged (0 hr) and imaged again at 24 hr post-scratch. In some experiments, at the 
0 hr timepoint, cells transfected with shRNA were additionally treated with 1% DMSO, 25 µM 






Supplemental Figure 10. FDA-approved drugs docked onto allosteric sites of PRL-3 in 
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Supplemental Table 2: Candesartan and Salirasib have no negative effect on  
activity of other phosphatases (at 25µM)  
       
Phosphatase Tested 
Percent Phosphatase Activity     
(compared to DMSO)     
  Candesartan Salirasib     
ACP1 (LMPTP-A)  97 96     
ACP1 (LMPTP-B) 113 106     
CD45  100 102     
Lambda PP  107 112     
MKP5  99 106     
PP1alpha  105 104     
PP2A  110 107     
PTP1B  109 114     
PTPbeta  85 91     
PTPMEG  109 107     
PTPMEG2  97 102     
PTPN22 136 129     
PTPRM  107 111     
SHP1 116 113     
SHP2  104 103     
TCPTP  128 118     
VHR  87 97     
Yoph  112 102     
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Bardoxolone-Me -10.44 22 -11.25 -0.23 +0.60 -0.44 1 
Bithionil -8.00 1370 -7.76 -1.98 +1.19 -0.54 1 
Candesartan -10.26 30 -12.54 -1.83 +2.39 -1.73 2 
Closantel -10.43 23 -11.42 -2.06 +1.19 -1.86 1 
Docusate -8.50 586 -13.00 -1.36 +5.37 -0.49 2 
Eltrombopag -11.29 5 -12.52 -1.81 +2.09 -0.96 2 
Hexachlorophene -8.48 605 -8.46 -1.92 +1.19 -0.71 1 
Idasanutlin -10.14 37 -10.79 -5.32 +2.68 -3.29 1 
Napabucasin -7.96 1470 -8.26 -0.13 +0.30 -0.13 1 
Salirasib -10.46 22 -12.86 -1.53 +3.28 -0.65 1 
YM155 -8.99 257 -9.99 -0.86 +1.49 -0.36 2 
Dexamethasone -8.49 596 -8.68 -1.58 +1.49 -0.28 1 





















Bardoxolone-Me -8.54 553 -8.90 -0.67 +0.60 -0.44 In 
Bithionil -7.74 2100 -8.82 -0.65 +1.19 -0.54 In 
Candesartan -8.51 577 -9.36 -3.27 +2.39 -1.73 In 
Closantel -9.00 254 -9.94 -2.1 +1.19 -1.86 In 
Docusate -8.38 726 -11.83 -2.38 +5.37 -0.46 O 
Eltrombopag -10.64 16 -11.80 -1.88 +2.09 -0.96 In 
Hexachlorophene -9.01 247 -9.02 -1.89 +1.19 -0.71 In 
Idasanutlin -9.65 84 -10.45 -5.2 +2.68 -3.31 In 
Napabucasin -6.70 12340 -6.99 -0.13 +0.30 -0.13 In 
Salirasib -9.00 253 -11.06 -1.87 +3.28 -0.65 In 
YM155 -7.92 1560 -8.65 -1.12 +1.49 -0.35 O 
Dexamethasone -7.87 1690 -8.35 -1.30 +1.49 -0.28 In 
Sigma Inhibitor -9.52 105 -10.36 -1.20 +1.19 -0.84 In 
a Estimated Free Energy = Intermolecular + Total Internal + Torsional – Unbound Energy 
b Autodock estimates inhibition constant from the estimated free energy 
c Site 1 and 2 refer to the allosteric sites (see text), while In and O refer to a site in between the loops, or outside of this area. 
 
  
Supplemental Table 4: Compounds used in this study 
Manufacturer Compound Catalog Number 
Selleck Hexachlorophene S4632 
Selleck Closantel S4106 
Selleck Candesartan Cilexetil S2037 
Selleck Vitamin B12 S1902 
Selleck Idasanutlin S7205 
Selleck Salirasib S7684 
Selleck YM155 S1130 
Selleck Closantel Sodium S4105 
Selleck Napabucasin S7977 
Selleck Bithionol S4552 
Selleck Eltrombag Olamine S2229 
Selleck Eltrombag   S4502 
Selleck Bardoxolone Methyl S8078 
Selleck Embelin S7025 
Selleck Docusate Sodium S4588 
Sigma PRL-3 Inhibitor I P0108 
Enamine Analog 3 Z44389470 
Enamine Thienopyridone EN300-171034 
 
